Shield Therapeutics Stock

Shield Therapeutics Stock by Ashly Chole last updated on February 07, 2026

Should You Buy Shield Therapeutics Stock?

The stock price of Shield Therapeutics gained 318% in just one year. The stock price went from 2.63p to near 11p in just 12 months and pushed the market cap above 100 million.

This rise in the stock price means Shield Therapeutics is no longer a penny stock but a small-cap! But what propelled the Shield Therapeutics stock higher, and can it do the same in 2026?

Shield Therapeutics' Product Has FDA Approval

Shield Therapeutics is in the pharma sector and mainly focuses on the treatment of iron deficiency. The company is also behind the famous brand ACCRUFeR.

What makes ACCRUFeR special is that it is the only oral iron product with an FDA approval. The latest data shows that around 20 million people in the USA suffer from iron deficiency, which means there's a huge market for this product.

The Q3 2025 data showed that the number of active users of ACCRUFeR was near 54,000. This led to a net revenue of $13.1 million with an 82% y/y increase.

If all things stay on the right track, Shield Therapeutics will have a positive free cash flow in 2026. Also, the losses of Shield Therapeutics are shrinking, which shows it is heading in the right direction.

There's no doubt that Shield Therapeutics has the 1st mover advantage. Also, the global market for iron products is worth $5.6 billion and will grow to $10.9 billion by 2034.

The only downside is that the main business of Shield Therapeutics is highly dependent on ACCRUFeR. This means that if the sales decline or another product gets FDA approval, it could affect the company's bottom line.

The bottom line is that both the growth prospects and the associated risks are high for the Shield Therapeutics stock. You can think of it as a high-risk and high-reward pharma stock.

So, for those investors who are willing to take the extra risk in exchange for high reward, Shield Therapeutics stock can be the right option.